Want to see SE:ISOFOL full AI Analyst Report?
ISOFOL Stock Chart & Stats
kr0.72
-kr0.10(-6.34%)
At close: 4:00 PM EST
kr0.72
-kr0.10(-6.34%)
Day’s Range― - ―
52-Week Rangekr0.55 - kr1.20
Previous CloseN/A
Volume134.77K
Average Volume (3M)291.00K
Market Cap
kr284.60M
Enterprise Valuekr118.51M
Total Cash (Recent Filing)kr114.83M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding320,491,640
10 Day Avg. Volume401,900
30 Day Avg. Volume291,002
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageThe absence of financial debt reduces immediate solvency and refinancing pressure while preserving flexibility for clinical development spending. Although the company remains loss-making, its low-leverage structure limits fixed financing obligations and provides a more stable base than a debt-funded biotech.
Positive Equity And Asset BasePositive equity and a substantial asset base provide some support for continued operations and clinical execution. This does not remove the need for funding, but it indicates that the company retains a capital foundation that can support development activities over the medium term.
Focused Oncology Development PlatformA focused oncology candidate gives Isofol a defined development strategy centered on improving established chemotherapy regimens. If clinical and regulatory objectives are achieved, the program could support future commercialization or partnering, creating a pathway beyond its current R&D model.
Bears Say
No Meaningful Commercial RevenueThe absence of meaningful product revenue leaves Isofol dependent on financing while its candidate remains in development. Until an approval or commercial agreement generates operating income, the company lacks a recurring revenue base to fund research, administration, and future expansion.
Persistent And Substantial LossesPersistent operating and net losses indicate that the current business model has not yet produced sustainable earnings. Continued deficits can erode the capital base and increase dependence on successful clinical progress, regulatory approval, or additional external financing.
Material Operating Cash BurnMaterially negative operating cash flow shows that Isofol consumes significant cash to sustain its activities rather than generating cash internally. This creates an ongoing funding requirement and makes the company’s ability to maintain development plans dependent on reserves or future capital access.
Isofol Medical AB News
ISOFOL FAQ
What was Isofol Medical AB’s price range in the past 12 months?
Isofol Medical AB lowest stock price was kr0.55 and its highest was kr1.20 in the past 12 months.
What is Isofol Medical AB’s market cap?
Isofol Medical AB’s market cap is kr284.60M.
When is Isofol Medical AB’s upcoming earnings report date?
Isofol Medical AB’s upcoming earnings report date is Nov 12, 2026 which is in 20 days.
How were Isofol Medical AB’s earnings last quarter?
Isofol Medical AB released its earnings results on Aug 25, 2026. The company reported -kr0.05 earnings per share for the quarter.
Is Isofol Medical AB overvalued?
According to Wall Street analysts Isofol Medical AB’s price is currently Overvalued.
Does Isofol Medical AB pay dividends?
Isofol Medical AB does not currently pay dividends.
What is Isofol Medical AB’s EPS estimate?
Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Isofol Medical AB have?
Isofol Medical AB has 320,491,640 shares outstanding.
What happened to Isofol Medical AB’s price movement after its last earnings report?
Isofol Medical AB reported an EPS of -kr0.05 in its last earnings report. Following the earnings report the stock price went up 1.327%.
Which hedge fund is a major shareholder of Isofol Medical AB?
Currently, no hedge funds are holding shares in SE:ISOFOL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Isofol Medical AB
Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is presently undergoing Phase 3 clinical trials for individuals with advanced colorectal cancer. The company has forged significant strategic alliances with organizations including Recipharm, Merck & Cie, and Sahlgrenska University Hospital. Established in 2008, its corporate base is situated in Gothenburg, Sweden.
Technical Analysis
BioInvent International AB
―
Oncopeptides AB
―
Elicera Therapeutics AB
―
Immunicum AB
―
Cantargia AB
―